Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol IDN-6556-18 - A Post Treatment Follow-up Study for Liver Disease Subjects With or Without Liver Cirrhosis After Receiving Emricasan or Placebo

NCT03479125 is registered in ClinicalTrials.gov with Conatus Pharmaceuticals Inc. as lead sponsor.

NCT NCT03479125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03479125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol IDN-6556-18 - A Post Treatment Follow-up Study for Liver Disease Subjects With or Without Liver Cirrhosis After Receiving Emricasan or Placebo
Lead sponsor
Conatus Pharmaceuticals Inc.
Phase
Observational
Overall status
Terminated
Start date
February 27, 2018
Completion date
September 30, 2019
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

decompensated non-alcoholic steatohepatitis cirrhosis, liver cirrhosis, liver diseases, liver fibrosis, nash fibrosis, orthotopic liver transplantation